SCRO

SCRO

Stockholm, Sweden· Est.
scro.se
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Aurevia is a specialized consulting and contract research organization (CRO) focused on regulatory affairs and clinical trial services for the healthcare, pharmaceutical, and medical technology sectors. Founded in 2018 (with roots from a previous entity), the company has over 25 years of combined experience, serving 200+ annual clients with a team of 100+ professionals. It operates a service-based business model, generating revenue by providing regulatory strategy, quality assurance, and full-service clinical trial management to help clients navigate complex global regulations and bring innovative products to market. The company is privately held and headquartered in Stockholm, Sweden.

CRISPRGene Therapy

Technology Platform

Integrated service platform offering expert consulting in clinical research (CRO) and medical technology regulatory compliance, supported by a professional training academy (Aurevia Academy).

Opportunities

Growing regulatory complexity for novel therapies (ATMPs, digital health) and new EU regulations (MDR/IVDR) drive sustained demand for specialized consulting.
Expansion of its training academy (Aurevia Academy) and geographic reach beyond the Nordics present scalable growth avenues.
The convergence of pharmaceuticals and medical devices creates a need for integrated service providers like Aurevia.

Risk Factors

Business is highly dependent on retaining expert talent in a competitive market.
Revenue is subject to client R&D budget cycles and potential concentration risk.
Intense competition from large global CROs and regulatory consultancies with greater resources.

Competitive Landscape

Competes with large global CROs (e.g., IQVIA, Parexel, PPD) and regulatory consultancies, as well as smaller niche firms and independent consultants specializing in Nordic/EU regulations. Differentiation is based on deep, integrated expertise in both clinical trials and MedTech/IVD regulatory affairs within the European framework.